---
figid: PMC6923785__mdz280f1
figlink: /pmc/articles/PMC6923785/figure/mdz280-F1/
number: F1
caption: 'Mechanisms of resistance to PI3K inhibitors in estrogen receptor (ER)-positive
  breast cancer and current and future drug combination strategies involving PI3K
  inhibitors. In PIK3CA-mutated breast tumours, resistance to PI3K inhibitors can
  be mediated by multiple mechanisms, including activation of alternative pathways
  that drive cell proliferation (e.g. RAS/MEK/ERK pathway, ER pathway, or HER2 pathway);
  by signalling via other PI3K isoforms when a specific subunit is blocked; by activation
  of downstream effectors in the PI3K pathway such as AKT and mTOR; by loss of regulators
  of PI3K signalling such as PTEN; or by epigenomic crosstalk between PI3K and ER
  pathways, resulting in upregulation of ER-dependent transcription. Ab, monoclonal
  antibody; AR, androgen receptor; CDK4/6i, CDK4/6 inhibitors; ER, estrogen receptor;
  HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor
  receptor 3; IGFR1, insulin growth factor receptor 1; mTOR, mTOR inhibitors; PI3Ki,
  PI3K inhibitors; SERD, selective estrogen receptor degraders; T-DM1, ado-trastuzumab
  emtansine; TKI, tyrosine kinase inhibitor. Dashed arrows, inhibitory function; bold
  arrows, activation function. Note: within each drug class, we have only included
  compounds that have been or that are currently being tested in combination with
  PI3K inhibitors in clinical trials (see Tables  and  for more details).'
pmcid: PMC6923785
papertitle: Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive
  breast cancer patients and combination therapies involving PI3K inhibitors.
reftext: M Brandão, et al. Ann Oncol. 2019 Dec;30(Suppl 10):x27-x42.
pmc_ranked_result_index: '3824'
pathway_score: 0.9285492
filename: mdz280f1.jpg
figtitle: Mechanisms of resistance to PI3K inhibitors in estrogen receptor (ER)-positive
  breast cancer and current and future drug combination strategies involving PI3K
  inhibitors
year: '2019'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6923785__mdz280f1.html
  '@type': Dataset
  description: 'Mechanisms of resistance to PI3K inhibitors in estrogen receptor (ER)-positive
    breast cancer and current and future drug combination strategies involving PI3K
    inhibitors. In PIK3CA-mutated breast tumours, resistance to PI3K inhibitors can
    be mediated by multiple mechanisms, including activation of alternative pathways
    that drive cell proliferation (e.g. RAS/MEK/ERK pathway, ER pathway, or HER2 pathway);
    by signalling via other PI3K isoforms when a specific subunit is blocked; by activation
    of downstream effectors in the PI3K pathway such as AKT and mTOR; by loss of regulators
    of PI3K signalling such as PTEN; or by epigenomic crosstalk between PI3K and ER
    pathways, resulting in upregulation of ER-dependent transcription. Ab, monoclonal
    antibody; AR, androgen receptor; CDK4/6i, CDK4/6 inhibitors; ER, estrogen receptor;
    HER2, human epidermal growth factor receptor 2; HER3, human epidermal growth factor
    receptor 3; IGFR1, insulin growth factor receptor 1; mTOR, mTOR inhibitors; PI3Ki,
    PI3K inhibitors; SERD, selective estrogen receptor degraders; T-DM1, ado-trastuzumab
    emtansine; TKI, tyrosine kinase inhibitor. Dashed arrows, inhibitory function;
    bold arrows, activation function. Note: within each drug class, we have only included
    compounds that have been or that are currently being tested in combination with
    PI3K inhibitors in clinical trials (see Tables  and  for more details).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ERBB2
  - ERBB3
  - EGFR
  - HRAS
  - KRAS
  - NRAS
  - ASS1
  - PTEN
  - TXK
  - ARAF
  - BRAF
  - RAF1
  - AKT2
  - AKT3
  - AKT1
  - MAP2K1
  - MAP2K2
  - MTOR
  - AR
  - RPS6KB1
  - MAPK3
  - MAPK1
  - CDK3
  - CDK5
  - CDK7
  - CDK9
  - CDK16
  - CDK17
  - CDK18
  - CDK14
  - CDKL5
  - CDK13
  - CDKL1
  - CDKL2
  - CDK20
  - CDKL3
  - CDK12
  - CDK15
  - CDKL4
  - CDK11A
  - CDK1
  - CDK11B
  - CDK2
  - CDK4
  - CDK6
  - CDK8
  - CDK10
  - CDK19
  - androgens
  - Enzalutamide
  - Lapatinib
  - AZD8186
  - MLN1117
  - Everolimus
  - Paclitaxel
  - paclitaxel
  - Docetaxel
  - Capecitabine
genes:
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: HER2
  symbol: HER2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: a/ß
  symbol: ASS
  source: hgnc_prev_symbol
  hgnc_symbol: ASS1
  entrez: '445'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: Anti-HER2/EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: TKI
  symbol: TKL
  source: hgnc_alias_symbol
  hgnc_symbol: TXK
  entrez: '7294'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: АКТ
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: МЕК
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: AR
  symbol: AR
  source: hgnc_symbol
  hgnc_symbol: AR
  entrez: '367'
- word: PS6K
  symbol: PS6K
  source: hgnc_alias_symbol
  hgnc_symbol: RPS6KB1
  entrez: '6198'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK3
  entrez: '1018'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK5
  entrez: '1020'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK7
  entrez: '1022'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK9
  entrez: '1025'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK16
  entrez: '5127'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK17
  entrez: '5128'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK18
  entrez: '5129'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK14
  entrez: '5218'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL5
  entrez: '6792'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK13
  entrez: '8621'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL1
  entrez: '8814'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL2
  entrez: '8999'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK20
  entrez: '23552'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL3
  entrez: '51265'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK12
  entrez: '51755'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK15
  entrez: '65061'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDKL4
  entrez: '344387'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK11A
  entrez: '728642'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK1
  entrez: '983'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK11B
  entrez: '984'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK2
  entrez: '1017'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK8
  entrez: '1024'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK10
  entrez: '8558'
- word: CDK
  symbol: CDK
  source: bioentities_symbol
  hgnc_symbol: CDK19
  entrez: '23097'
- word: CDK4/6
  symbol: CDK4
  source: hgnc_symbol
  hgnc_symbol: CDK4
  entrez: '1019'
- word: CDK4/6
  symbol: CDK6
  source: hgnc_symbol
  hgnc_symbol: CDK6
  entrez: '1021'
chemicals:
- word: androgens
  source: MESH
  identifier: D000728
- word: Enzalutamide
  source: MESH
  identifier: C540278
- word: Lapatinib
  source: MESH
  identifier: C490728
- word: AZD8186
  source: MESH
  identifier: C000595972
- word: MLN1117
  source: MESH
  identifier: C492532
- word: Everolimus
  source: MESH
  identifier: C107135
- word: Paclitaxel
  source: MESH
  identifier: D017239
- word: paclitaxel
  source: MESH
  identifier: D017239
- word: Docetaxel
  source: MESH
  identifier: C067311
- word: Capecitabine
  source: MESH
  identifier: C110904
diseases: []
figid_alias: PMC6923785__F1
redirect_from: /figures/PMC6923785__F1
figtype: Figure
---
